MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Akcijų sąrašas・ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

85.4 1.2

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

83.71

Max

85.93

Pagrindiniai rodikliai
By Trading Economics
Pajamos	18M 27M
Pardavimai	16M 228M
P/E Sektoriaus vid.	53.019 89.037
Pelno marža	11.684
Darbuotojai	897
EBITDA	19M 61M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+34.08% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-192M 1.9B
Ankstesnė atidarymo kaina	84.2
Ankstesnė uždarymo kaina	85.4

Naujienos nuotaikos

By Acuity

63%

37%

321 / 360 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

70.05 / 71.85 Palaikymas ir pasipriešinimas

ANI Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-21 23:49; UTC

Pagrindinės rinkos jėgos

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

2026-01-21 21:12; UTC

Pagrindinės rinkos jėgos

Automaker Stocks Rise After Trump Calls Off European Tariffs

2026-01-21 21:00; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

2026-01-21 20:29; UTC

Pagrindinės rinkos jėgos

Chip Makers Gain After Trump Calls Off European Tariffs

2026-01-21 20:04; UTC

Pagrindinės rinkos jėgos

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

2026-01-21 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

2026-01-21 23:34; UTC

Rinkos pokalbiai

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

2026-01-21 22:39; UTC

Uždarbis

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

2026-01-21 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-21 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-21 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

2026-01-21 21:19; UTC

Uždarbis

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

2026-01-21 20:45; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Borse Group to Acquire Allfunds for $6.19B

2026-01-21 20:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

2026-01-21 20:31; UTC

Rinkos pokalbiai

Oil Settles Higher With Support From Heating Fuel -- Market Talk

2026-01-21 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

2026-01-21 20:27; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-21 20:27; UTC

Rinkos pokalbiai

Was It a 'TACO' Event? -- Market Talk

2026-01-21 20:26; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

2026-01-21 20:23; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

2026-01-21 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

2026-01-21 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Group Agrees to Buy Allfunds

2026-01-21 20:08; UTC

Uždarbis

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

2026-01-21 20:03; UTC

Rinkos pokalbiai

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

2026-01-21 19:51; UTC

Rinkos pokalbiai

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

2026-01-21 19:43; UTC

Rinkos pokalbiai

U.S. Ethanol Production Expected to Slip -- Market Talk

2026-01-21 19:31; UTC

Rinkos pokalbiai

Gold Settles at Fresh All-Time High -- Market Talk

2026-01-21 19:24; UTC

Uždarbis

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

2026-01-21 19:10; UTC

Rinkos pokalbiai

Mexican Inflation Seen Picking Up in Early January -- Market Talk

2026-01-21 18:57; UTC

Rinkos pokalbiai

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Akcijų palyginimas

Kainos pokytis

ANI Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

34.08% į viršų

12 mėnesių prognozė

Vidutinis 115 USD 34.08%

Aukščiausias 124 USD

Žemiausias 100 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ANI Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių ANI Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

70.05 / 71.85Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

Rinkos nuotaikos

By Acuity

321 / 360 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.